ONCY - Oncolytics Biotech

-

$undefined

N/A

(N/A)

Oncolytics Biotech NasdaqCM:ONCY Oncolytics Biotech Inc., a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of oncology treatments. The company develops pelareorep, an intravenously delivered immunotherapeutic agent for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative advanced and metastatic breast cancer, metastatic pancreatic ductal adenocarcinoma, and anal cancer. It has an agreement with Roche Holding AG to supply its immune checkpoint inhibitors, atezolizumab, for use in its ongoing sponsored studies. Oncolytics Biotech Inc. was incorporated in 1998 and is headquartered in Calgary, Canada.

Location: 322 11th Avenue SW, Calgary, AB, T2R 0C5, Canada | Website: https://oncolyticsbiotech.com | Industry: Biotechnology | Sector: Healthcare


Market Cap

NaN

52 Wk Range

$ - $

Previous Close

$N/A

Open

$N/A

Day Range

N/A - N/A

Volume

N/A

Avg Volume

N/A

Enterprise Value

18.06M

Cash

15.3M

Avg Qtr Burn

-6.499M

Short % of Float

2.61%

Insider Ownership

3.92%

Institutional Own.

1.53%

Qtr Updated

03/31/25


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date

Phase 3

Initiation

Phase 3

Initiation

Pelareorep + Retifanlimab Details
Breast cancer, Triple-negative breast cancer

Phase 2

Update

Phase 1/2

Data readout

Phase 1/2

Data readout

Pelareorep + Keytruda® Details
Pancreatic cancer, Sarcoma

Failed

Discontinued

Failed

Discontinued